# LungTIME-C01 (NCT05549037)

> Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05549037
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hunan Province Tumor Hospital
- Conditions: Non-small Cell Lung Cancer
- Interventions: Pembrolizumab, Sintilimab
- Enrollment: 210
- Primary outcome: Progression-free survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=lungtime-c01-nct05549037

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05549037", "email": "<work email>"}; the inbox owner confirms by the emailed link.